III-2 300 Aim: To investigate the potential value The median MoM TNF-R1 was () of maternal serum concentration of significantly increased at both 11-13 tumour necrosis factor receptor 1 weeks (1.094 MoM versus 1.003 MoM) at 30-33 weeks' gestation in the and at 30-33 weeks (1.101 MoM versus prediction of PE developing at or after 1.006 MoM). In screening for PE by a 34 weeks. combination of maternal characteristics and serum TNF-R1 at Methods: Serum TNF-R1 was measured 30-33 weeks, the estimated detection at 11-13 and at 30-33 weeks' gestation rates of PE at false positive rate of 10% in a case-control study of 50 cases that was 40.0% (26.4–54.8). developed PE at or after 34 weeks and 250 unaffected controls. The measured values of TNF-R1 were converted into multiples of the normal median (MoM) and the MoM values in the PE and control groups were compared. Cohort III-2 2,140 PE Aim: To assess risk for PE based on In pregnancies with PE the log10 MoM () maternal characteristics, MAP and Ut-PI values of MAP and Ut-PI were 83,615 at 30-33 weeks' gestation. inversely related to gestational age at control delivery. Biophysical testing detected Methods: We developed a survival time 89.7, 65.4 and 53.3% of PE with model for the time of delivery for PE by delivery within 4, 6 and 8 weeks of the combination of maternal visit, at a fixed false-positive rate of characteristics and history with MAP 5%. and Ut-PI multiple of the median (MoM) values (biophysical test). Data on MAP and Ut-PI were available in 350 cases of PE and 13,878 of the normal group. The detection rate of PE requiring delivery within 4, 6 and 8 weeks of the visit was estimated.
() III-2 300 Aim: To investigate the potential value of maternal serum concentration of tumour necrosis factor receptor 1 at 30-33 weeks' gestation in the prediction of PE developing at or after 34 weeks. Methods: Serum TNF-R1 was measured at 11-13 and at 30-33 weeks' gestation in a case-control study of 50 cases that developed PE at or after 34 weeks and 250 unaffected controls. The measured values of TNF-R1 were converted into multiples of the normal median (MoM) and the MoM values in the PE and control groups were compared. The median MoM TNF-R1 was significantly increased at both 11-13 weeks (1.094 MoM versus 1.003 MoM) and at 30-33 weeks (1.101 MoM versus 1.006 MoM). In screening for PE by a combination of maternal characteristics and serum TNF-R1 at 30-33 weeks, the estimated detection rates of PE at false positive rate of 10% was 40.0% (26.4–54.8). () Cohort III-2 2,140 PE 83,615 control Aim: To assess risk for PE based on maternal characteristics, MAP and Ut-PI at 30-33 weeks' gestation. Methods: We developed a survival time model for the time of delivery for PE by combination of maternal characteristics and history with MAP and Ut-PI multiple of the median (MoM) values (biophysical test). Data on MAP and Ut-PI were available in 350 cases of PE and 13,878 of the normal group. The detection rate of PE requiring delivery within 4, 6 and 8 weeks of the visit was estimated. In pregnancies with PE the log10 MoM values of MAP and Ut-PI were inversely related to gestational age at delivery. Biophysical testing detected 89.7, 65.4 and 53.3% of PE with delivery within 4, 6 and 8 weeks of the visit, at a fixed false-positive rate of 5%.